Kong SY - Search Results

1

Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.

Sung C, An J, Lee S, Park J, Lee KS, Kim IH, Han JY, Park YH, Kim JH, Kang EJ, Hong MH, Kim TY, Lee JC, Lee JL, Yoon S, Choi CM, Lee DH, Yoo C, Kim SW, Jeong JH, Seo S, Kim SY, Kong SY, Choi JK, Park SR. Sung C, et al. Among authors: kong sy. Nat Cancer. 2023 Jun;4(6):844-859. doi: 10.1038/s43018-023-00572-5. Epub 2023 Jun 12. Nat Cancer. 2023. PMID: 37308678

2

Epidermal growth factor receptor status in anaplastic thyroid carcinoma.

Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, Park SH, Keam B, Park DJ, Cho BY, Kim SW, Chung KW, Lee ES, Kim SW. Lee DH, et al. Among authors: kong sy. J Clin Pathol. 2007 Aug;60(8):881-4. doi: 10.1136/jcp.2006.041251. Epub 2006 Nov 1. J Clin Pathol. 2007. PMID: 17079354 Free PMC article.

3

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, Park SR. Kong SY, et al. Pharmacogenomics. 2009 Jul;10(7):1147-55. doi: 10.2217/pgs.09.48. Pharmacogenomics. 2009. PMID: 19604090 Clinical Trial.

4

Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60.

Park SR, Cho HJ, Moon KJ, Chun KH, Kong SY, Yoon SS, Lee JS, Park S. Park SR, et al. Among authors: kong sy. Leuk Lymphoma. 2010 Jan;51(1):132-45. doi: 10.3109/10428190903383419. Leuk Lymphoma. 2010. PMID: 20001229

5

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH. Park SR, et al. Among authors: kong sy. Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0. Epub 2013 Aug 28. Cancer Chemother Pharmacol. 2013. PMID: 23982118 Clinical Trial.

6

A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.

Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. Kim YW, et al. Among authors: kong sy. Gastric Cancer. 2016 Apr;19(2):586-596. doi: 10.1007/s10120-015-0490-3. Epub 2015 Apr 8. Gastric Cancer. 2016. PMID: 25851942 Clinical Trial.

7

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.

Jeong JH, Park SR, Ahn Y, Ryu MH, Ryoo BY, Kong SY, Yook JH, Yoo MW, Kim BS, Kim BS, Kang YK. Jeong JH, et al. Among authors: kong sy. Gastric Cancer. 2017 Jan;20(1):146-155. doi: 10.1007/s10120-015-0586-9. Epub 2015 Dec 29. Gastric Cancer. 2017. PMID: 26715117

8

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.

Kim SY, Baek JY, Oh JH, Park SC, Sohn DK, Kim MJ, Chang HJ, Kong SY, Kim DY. Kim SY, et al. Among authors: kong sy. Radiat Oncol. 2017 Mar 27;12(1):62. doi: 10.1186/s13014-017-0800-5. Radiat Oncol. 2017. PMID: 28347333 Free PMC article. Clinical Trial.

9

A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.

Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, Kong SY, Park YI. Park SR, et al. Among authors: kong sy. Eur J Cancer. 2017 Sep;83:32-42. doi: 10.1016/j.ejca.2017.06.008. Epub 2017 Jul 14. Eur J Cancer. 2017. PMID: 28711577 Clinical Trial.

10

A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.

Kim MJ, Kong SY, Nam BH, Kim S, Park YI, Park SR. Kim MJ, et al. Among authors: kong sy. Pharmacogenet Genomics. 2018 Jan;28(1):23-30. doi: 10.1097/FPC.0000000000000320. Pharmacogenet Genomics. 2018. PMID: 29189588 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

307 results

Search Page